The role of tetramerization in p53 function
暂无分享,去创建一个
[1] X. Chen,et al. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. , 1993, Genes & development.
[2] C. Arrowsmith,et al. Thermodynamic analysis of the structural stability of the tetrameric oligomerization domain of p53 tumor suppressor. , 1995, Biochemistry.
[3] C. Miller,et al. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription , 1993, Molecular and cellular biology.
[4] T. Davison,et al. Characterization of the oligomerization defects of two p53 mutants found in families with Li–Fraumeni and Li–Fraumeni-like syndrome , 1998, Oncogene.
[5] E. Appella,et al. Signaling to p53: breaking the posttranslational modification code. , 2000, Pathologie-biologie.
[6] P. Chène,et al. Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties. , 1999, Journal of molecular biology.
[7] M. Grütter,et al. Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. , 1998, Acta crystallographica. Section D, Biological crystallography.
[8] K. McLure,et al. How p53 binds DNA as a tetramer , 1998, The EMBO journal.
[9] J. Garin,et al. The in vitro phosphorylation of p53 by calcium-dependent protein kinase C--characterization of a protein-kinase-C-binding site on p53. , 1997, European journal of biochemistry.
[10] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[11] A. Gronenborn,et al. The oligomerization domain of p53: Crystal structure of the trigonal form , 1996, FEBS letters.
[12] T. Halazonetis,et al. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. , 1995, The EMBO journal.
[13] D. Lane,et al. The p53 tumour suppressor gene , 1998, The British journal of surgery.
[14] K. Vousden,et al. Mechanisms of p53-mediated apoptosis , 1999, Cellular and Molecular Life Sciences CMLS.
[15] D. Simmons,et al. Characterization of the in vitro interaction between SV40 T antigen and p53: mapping the p53 binding site. , 1988, Virology.
[16] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[17] C Béroud,et al. p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis , 2000, Human mutation.
[18] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[19] M. Malanga,et al. Poly(ADP-ribose) Binds to Specific Domains of p53 and Alters Its DNA Binding Functions* , 1998, The Journal of Biological Chemistry.
[20] T. Halazonetis,et al. Wild‐type p53 adopts a ‘mutant’‐like conformation when bound to DNA. , 1993, The EMBO journal.
[21] C. Prives,et al. p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.
[22] K. McLure,et al. p53 DNA binding can be modulated by factors that alter the conformational equilibrium , 1999, The EMBO journal.
[23] A. Gronenborn,et al. Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[24] M. Vidal,et al. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[25] T. Davison,et al. p73 and p63 Are Homotetramers Capable of Weak Heterotypic Interactions with Each Other but Not with p53* , 1999, The Journal of Biological Chemistry.
[26] P. Tegtmeyer,et al. Interaction of p53 with its consensus DNA-binding site , 1995, Molecular and cellular biology.
[27] V. Zhurkin,et al. p53-induced DNA bending and twisting: p53 tetramer binds on the outer side of a DNA loop and increases DNA twisting. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[28] A. Levine,et al. Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73* , 2000, The Journal of Biological Chemistry.
[29] C. Pabo,et al. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.
[30] B. Gusterson,et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.
[31] D. Lane,et al. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.
[32] J. E. Stenger,et al. p53 oligomerization and DNA looping are linked with transcriptional activation. , 1994, The EMBO journal.
[33] G. Wahl,et al. A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking , 1999, The EMBO journal.
[34] M. Blagosklonny,et al. p53 from complexity to simplicity: mutant p53 stabilization, gain‐of‐function, and dominant‐negative effect , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[35] T. Yamashita,et al. The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. , 1997, Cancer research.
[36] N. Horikoshi,et al. Blockage by Adenovirus E4orf6 of Transcriptional Activation by the p53 Tumor Suppressor , 1996, Science.
[37] C. Prives,et al. p53: puzzle and paradigm. , 1996, Genes & development.
[38] H. Sakamoto,et al. Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[39] M. Hollstein,et al. p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.
[40] A. Levine,et al. The Spectrum of Mutations at the p53 Locus , 1995, Annals of the New York Academy of Sciences.
[41] C. Surridge. Forewarned is four-armed , 1994, Nature.
[42] P. Slootweg,et al. Gain-of-function mutations in the tumor suppressor gene p53. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] A M Gronenborn,et al. Interhelical angles in the solution structure of the oligomerization domain of p53: correction , 1995, Science.
[44] K. Wiman,et al. p53: a cell cycle regulator activated by DNA damage. , 1995, Advances in cancer research.
[45] V. Rotter,et al. Introduction: p53 – the first twenty years , 1999, Cellular and Molecular Life Sciences CMLS.
[46] G. Marius Clore,et al. Refined solution structure of the oligomerization domain of the tumour suppressor p53 , 1995, Nature Structural Biology.
[47] N. Pavletich,et al. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms , 1995, Science.
[48] R. Camplejohn,et al. Characterization of p53 oligomerization domain mutations isolated from Li–Fraumeni and Li–Fraumeni like family members , 1998, Oncogene.
[49] X. Sun,et al. p300/CBP-dependent and -independent transcriptional interference between NF-kappaB RelA and p53. , 2000, Biochemical and biophysical research communications.
[50] H. Sakamoto,et al. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. , 1997, Biochemistry.
[51] A. Fersht,et al. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain , 1998, The EMBO journal.
[52] P. Friedman,et al. The p53 protein is an unusually shaped tetramer that binds directly to DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[53] P. Chène,et al. p53 mutants without a functional tetramerisation domain are not oncogenic. , 1999, Journal of molecular biology.
[54] J. Varley,et al. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family , 1997, Oncogene.
[55] D. Meek,et al. Mechanisms of switching on p53: a role for covalent modification? , 1999, Oncogene.
[56] E. Stavridi,et al. Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions , 1999, Protein science : a publication of the Protein Society.
[57] A. Gronenborn,et al. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. , 1994, Science.
[58] C. Maki. Oligomerization Is Required for p53 to be Efficiently Ubiquitinated by MDM2* , 1999, The Journal of Biological Chemistry.
[59] Xuan Liu,et al. Stimulation of p53 DNA Binding by c-Abl Requires the p53 C Terminus and Tetramerization , 2000, Molecular and Cellular Biology.
[60] D. Pim,et al. Interaction between the HPV-16 E2 transcriptional activator and p53 , 1999, Oncogene.
[61] P. Chène. Influence of the N-terminal region on the oligomerisation between human and Xenopus laevis p53. , 1999, Journal of molecular biology.
[62] T. Halazonetis,et al. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. , 1993, The EMBO journal.
[63] P. Hainaut,et al. New approaches to understanding p53 gene tumor mutation spectra. , 1999, Mutation research.
[64] R. Tjian,et al. SV40 T antigen binds specifically to a cellular 53 K protein in vitro , 1981, Nature.
[65] P. Y. Chou,et al. Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins. , 1974, Biochemistry.
[66] O. Halevy,et al. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 , 1990, Cell.
[67] Alan R. Fersht,et al. Mechanism of folding and assembly of a small tetrameric protein domain from tumor suppressor p53 , 1999, Nature Structural Biology.
[68] K. Roemer,et al. Function, oligomerization, and conformation of tumor‐associated p53 proteins with mutated C‐terminus , 2000, Journal of cellular biochemistry.
[69] O. Halevy,et al. Stabilization of the p53 transformation-related protein in mouse fibrosarcoma cell lines: effects of protein sequence and intracellular environment , 1989, Molecular and cellular biology.
[70] A. Levine,et al. Mapping of the p53 and mdm-2 interaction domains. , 1993, Molecular and cellular biology.
[71] D. Lane,et al. Regulation of the specific DNA binding function of p53 , 1992, Cell.
[72] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[73] J. Milner,et al. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.
[74] J. E. Stenger,et al. Formation of stable p53 homotetramers and multiples of tetramers , 1992, Molecular carcinogenesis.
[75] P. Chène,et al. Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain , 1998, International journal of cancer.
[76] E. Shaulian,et al. Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. , 1993, The EMBO journal.
[77] M. Hixon,et al. Gain of function properties of mutant p53 proteins at the mitotic spindle cell cycle checkpoint. , 2000, Histology and histopathology.
[78] J. E. Stenger,et al. p53 domains: identification and characterization of two autonomous DNA-binding regions. , 1993, Genes & development.
[79] J. Cleveland,et al. Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain , 1998, Molecular and Cellular Biology.
[80] A. Fersht,et al. Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[81] M. Grütter,et al. In vitro structure-function analysis of the beta-strand 326-333 of human p53. , 1997, Journal of molecular biology.
[82] R. Kanamaru,et al. Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells. , 1997, Biochemical and biophysical research communications.
[83] M. Kubbutat,et al. Regulation of Mdm2-Directed Degradation by the C Terminus of p53 , 1998, Molecular and Cellular Biology.
[84] J. Milner,et al. Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135. , 1990, Journal of molecular biology.
[85] S. Deb,et al. `Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain , 1998, Oncogene.
[86] P. Chène. In vitro analysis of the dominant negative effect of p53 mutants. , 1998, Journal of molecular biology.
[87] C. Arrowsmith,et al. Solution structure of the tetrameric minimum transforming domain of p53 , 1995, Nature Structural Biology.
[88] M. Oren,et al. Oligomerization of oncoprotein p53 , 1988, Journal of virology.
[89] K. Roemer. Mutant p53: Gain-of-Function Oncoproteins and Wild-Type p53 Inactivators , 1999, Biological chemistry.